Drug Trial Radar · NCT04374136
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
119
Actual
Start
Jul 23, 2020
Primary completion
Sep 1, 2025
Study completion Jan 6, 2026
Sponsor
- Lead sponsor
- Alector Inc.Industry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Conditions
- Frontotemporal Dementia
Interventions
Part 1 Blinded - AL001Drug
Administered via intravenous (IV) infusion
Part 1 Blinded - PlaceboDrug
Administered via intravenous (IV) infusion
Part 2 (OLE Treatment) - AL001Drug
Administered via intravenous (IV) infusion
Part 2 (OLE Treatment) - Placebo Switched to AL001Drug
Administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic PatientsTime frame: Through study completion, on average up to 96 weeks
- Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic PatientsTime frame: Baseline to 96 weeks
- Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the StudyTime frame: 96 weeks
Locations
44 sites in 16 countries. Site status is shown where the registry gives one.
Dignity Health
Phoenix, Arizona
University of California San Diego
La Jolla, California
University of Colorado
Aurora, Colorado
Emory University
Atlanta, Georgia
Indiana University Health Neuroscience Center
Indianapolis, Indiana
University of Kansas Alzheimer's Disease Center
Fairway, Kansas
Johns Hopkins University School of Medicine
Baltimore, Maryland
Mayo Comprehensive Cancer Center - PPDS
Rochester, Minnesota
Irving Institute for Clinical and Translational Research
New York, New York
University Of Cincinnati Gardner Neuroscience institute
Cincinnati, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Houston Methodist Institute for Academic Medicine
Houston, Texas
Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia
Buenos Aires, Argentina
Box Hill Hospital
Box Hill, Australia
The Queen Elizabeth Hospital
Woodville, Australia
UZ Leuven
Leuven, Vlaams Brabant, Belgium
The University of Western Ontario
London, Canada
Sunnybrook Research Institute - University of Toronto
Toronto, Canada
CHU de Bordeaux
Bordeaux, France
CHRU Lille
Lille, France
Groupe Hospitalier Pitié Salpétrière
Paris, France
Uniklinik Köln
Cologne, Germany
Universitätsklinikum Ulm
Ulm, Germany
Eginitio University General Hospital of Athens - 1st University Neurology Clinic
Athens, Attica, Greece
University General Hospital of Alexandroupolis - Department of Neurology
Alexandroupoli, Evros, Greece
Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara
Baggiovara, Italy
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
Brescia, Italy
IRCCS - Centro S. Giovanni di Dio Fatebenefratelli
Brescia, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
Milan, Italy
PIA Fondazione Panico
Tricase, Italy
Erasmus MC
Rotterdam, Netherlands
Centro Hospitalar E Universitário de Coimbra EPE
Coimbra, Portugal
Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
Lisbon, Portugal
Hospital CUF Descobertas
Lisbon, Portugal
Centro Hospitalar do Porto - Hospital de Santo António
Porto, Porto District, Portugal
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitario de Donostia
Donostia / San Sebastian, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.